Scott+Scott Attorneys at Law LLP Alerts Investors There Is an Ongoing Securities Action Against Iovance Biotherapeutics, Inc. (IOVA)

A securities class action lawsuit has been filed against Iovance Biotherapeutics (NASDAQ: IOVA) alleging the company made false and misleading statements regarding the commercialization of its lead product, Amtagvi. The complaint asserts that undisclosed issues with Authorized Treatment Centers and patient retention led to higher costs and lower revenue, which became evident when Iovance reported a sharp decline in Q1 2025 product revenue to $49.3 million and significantly cut its FY2025 guidance from $450M-$475M to $250M-$300M. Following this disclosure, IOVA's stock price plummeted 44.8% on May 9, 2025.

Analysis

Iovance Biotherapeutics (IOVA) is facing a significant crisis of confidence following the disclosure of severe operational problems with the commercial launch of its key cell therapy, Amtagvi. The catalyst was the company's Q1 2025 financial report, which revealed a sharp sequential decline in product revenue to $49.3 million from $73.7 million in the prior quarter. More damaging was the drastic reduction of its full-year 2025 revenue guidance to a range of $250-$300 million, a cut of approximately 40% from the previous forecast of $450-$475 million. The company's own explanation, citing slower-than-expected ramp-ups at new Authorized Treatment Centers (ATCs) and challenges with treatment timelines, directly corroborates the core allegations of a newly filed securities class action lawsuit. The lawsuit claims management misled investors about the effectiveness of its sales and treatment network, which reportedly struggled with patient identification and retention. The market's response was immediate and severe, with the stock collapsing 44.8% on heavy volume, indicating that investors are now pricing in a substantially longer and more difficult path to commercial success and questioning management's credibility.

Key Decisions for Investors

• Investors should recognize that the 40% reduction in FY25 revenue guidance represents a fundamental breakdown of the initial investment thesis for Amtagvi's launch, warranting a complete reassessment of the company's valuation and growth trajectory.
• The pending securities class action lawsuit introduces a material legal and financial overhang, and potential investors should remain on the sidelines until there is clear evidence that the underlying operational bottlenecks at Authorized Treatment Centers have been resolved.
• Monitor future management commentary and quarterly results for specific metrics on new ATC activation rates and patient drop-off figures, as these will be the leading indicators of a potential stabilization or further deterioration in the commercial launch.